Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogs, high-affinity ligands for the haloperidol-sensitive .sigma. receptor
作者:Michael W. Scherz、Michelle Fialeix、James B. Fischer、N. Laxma Reddy、Alfred C. Server、Mark S. Sonders、Barbara C. Tester、Eckard Weber、Scott T. Wong、John F. W. Keana
DOI:10.1021/jm00171a016
日期:1990.9
2-CH3C6H5). Replacement of one or both aryl rings with certain saturated carbocycles (e.g. cyclohexyl, norbornyl, or adamantyl) leads to a significant increase in affinity. By combining the best aromatic and best saturated carbocyclic substituents in the same molecule, we arrived at some of the most potent sigma ligands described to date (e.g. N-exo-2-norbornyl-N'-(2-iodophenyl)guanidine, IC50 = 3 nM vs [3H]-3)
着眼于新型非典型抗精神病药的开发,我们研究了氟哌啶醇敏感的sigma受体的N,N'-二-邻甲苯基胍(DTG,3)及其同类物的结构亲和力关系。合成了许多DTG类似物,并在豚鼠脑膜匀浆的体外放射性配体置换实验中使用了高sigma特异性放射性配体[3H] -3和[3H]-(+)-3-(3-羟苯基)进行了评估。 -N-(1-丙基)哌啶和苯环利定(PCP)受体特异性化合物[3H] -N- [1-(2-噻吩基)-环己基]哌啶和[3H]-(+)-5-甲基-10 ,11-二氢-5H-二苯并[a,d]环庚烯-5,10-亚胺。N,N'-二芳基胍对sigma受体的亲和力随邻位取代基的体积比C2H5大而增加。疏水取代基通常优于类似位置的亲水取代基。此外,电子中性取代基优于强电子给体或吸电子基团。只要胍的至少一侧带有优选基团(例如2-CH 3 C 6 H 5),通常就可以保持与σ受体的显着结合。用某些饱和的碳环(例
Derivatives of 3-amino-pregn-5-ene
申请人:Roussel Uclaf
公开号:US04444767A1
公开(公告)日:1984-04-24
A compound selected from the group consisting of: 3-amino-.DELTA..sup.5 -pregnenes of the formula I: ##STR1## wherein X is selected from the group of ##STR2## the wavy lines indicate that the group may be in the .alpha.-or .beta.-position, R.sub.1 is selected from the group consisting of hydrogen and hydroxyalkyl or 2 to 5 carbon atoms, R.sub.2 is selected from the group consisting of hydrogen, hydroxyalkyl of 2 to 5 carbon atoms, acyl of an aliphatic carboxylic acid of 3 to 8 carbon atoms, alkoxycarbonyl of 2 to 8 carbon atoms, acyl of an .alpha.-amino-carboxylic acid or from a peptide of 2 to 3 amino acids of which amines may be either unsubstituted or mono-or disubstituted with alkyl of 1 to 5 carbon atoms with the proviso that R.sub.1 and R.sub.2 are not both hydrogen and that if the 3-amino group is in the .beta.-position, (i) when X is ##STR3## R.sub.1 and R.sub.2 are not both hydroxyethyl or (ii) when X is ##STR4## and R.sub.1 is hydrogen, R.sub.2 is not ethoxycarbonyl, the compound of the formula I wherein X is ##STR5## R.sub.1 is hydrogen and R.sub.2 is methyl, the 3-amino group is in the .alpha.-position and their non-toxic, pharmaceutically acceptable acid addition salts which are useful as stimulants of the mammalian immune system.